Linked Life Data

15314548

Source:http://linkedlifedata.com/resource/pubmed/id/15314548

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2004-8-17
pubmed:abstractText
The effect of adjuvant immunochemotherapy including OK-432 (Picibanil) on survival was assessed in patients who underwent curative resection of gastric cancer. Patients enrolled in this randomized controlled study were randomly assigned to group A or group B. Group A patients received 800 mg/d 5'-DFUR (Furtulon) for 2 years from 2 weeks after the operation. Group B patients received OK-432 plus 5'-DFUR by the same regimen as in group A. This study enrolled 288 patients, and 1 patient with malignant lymphoma was excluded. Among the remaining 287 patients, 143 and 144 were allocated to group A and group B, respectively, and their data were included in statistical analysis. The 5-year survival rates for groups A and B were 62.9% and 63.8%, respectively, showing no significant difference (P = 0.7996).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1524-9557
pubmed:author
pubmed:copyrightInfo
Copyright 2004 Lippincott Williams & Wilkins
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
394-7
pubmed:dateRevised
2008-3-18
pubmed:meshHeading
pubmed:articleTitle
A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer.
pubmed:affiliation
First Department of Surgery, School of Medicine, Hokkaido University, Sapporo, Japan. yuchan@med.hokudai.ac.jp
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial